Abstract:RationaleProteomics and metabolomics are widely used in the study of diabetes, but rarely in prediabetes research. This study aimed to explore the mechanisms of early-onset type 2 diabetes mellitus (T2DM) by analyzing proteomic changes at different stages of glucose metabolism. MethodsA total of 40 individuals undergoing routine physical health examinations between December 2016 and April 2017 were enrolled. Subjects were divided into four groups based on fasting blood glucose (FPG) levels: FPG < 5.6 mmol/L (group A); FPG >= 5.6 mmol/L and <6.1 mmol/L (group B); FPG >= 6.1 mmol/L and <7.0 mmol/L (group C); and FPG >= 7.0 mmol/L (group D). Each group had 10 cases. Sera from these 40 subjects were analyzed by label-free quantitative liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS). LC/MS/MS with selected reaction monitoring mode was also performed for qualitative and quantitative metabolomics analysis. Differentially expressed proteins were identified. Partial least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were used to analyze the differentially expressed metabolites. ResultsA total of 202 differentially expressed proteins were screened and were identified as mainly secreted proteins. Comparing group A with group B, 32 proteins were up-regulated and 18 proteins were down-regulated. Comparing group A with group C, 24 proteins were up-regulated and 24 proteins were down-regulated. Comparing group A with group D, 19 proteins were up-regulated and 17 proteins were down-regulated. The fold change for up-regulated proteins was >1.2, p < 0.05, while the fold change for down-regulated proteins was <-1.2, p < 0.05. PLS-DA and OPLS-DA revealed 113 differentially expressed metabolites. Correlation analysis of differentially expressed metabolites of group A versus group B revealed that among the down-regulated differential proteins, transforming growth factor beta-induced protein ig-h3 correlated negatively with metabolite L-saccharin, while among the up-regulated differential proteins, apolipoprotein C-IV correlated negatively with metabolite 3-methyloxindole. Among all differentially expressed proteins, 19 proteins were associated with early initiation of chronic inflammation, including CD14 and CSF-1R, which were newly identified in the early onset of T2DM. ConclusionsMany proteins are differentially expressed between prediabetes and after T2DM diagnosis, although the specific mechanism remains unclear. The expression level of CD14 was significantly up-regulated and that of CSF-1R was significantly down-regulated when FPG was >= 5.6 mmol/L, suggesting that CD14 and CSF-1R may be important markers for early-onset T2DM and may serve as new targets for T2DM treatment.

Serum Biomarker of Diabetic Peripheral Neuropathy Indentified by Differential Proteomics

Analysis of Urinary Proteomic Patterns for Diabetic Nephropathy by ProteinChip.

Lower Serum Branched-Chain Amino Acid Catabolic Intermediates Are Predictive Signatures Specific to Patients with Diabetic Foot.

Analysis of Protein Expression Changes in Patients with Prediabetes Using Proteomics Approaches.

Characterization of the Metabolic Proteome of Serum From Patients With Diabetic Distal Symmetric Polyneuropathy

Analysis of urinary proteomic patterns for type 2 diabetic nephropathy by ProteinChip.

Gene Expression Profiling Reveals Candidate Biomarkers and Probable Molecular Mechanism in Diabetic Peripheral Neuropathy

Phospholipidomic Identification of Potential Plasma Biomarkers Associated with Type 2 Diabetes Mellitus and Diabetic Nephropathy.

Diagnostic biomarker for type 2 diabetic peripheral neuropathy via comprehensive bioinformatics analysis

Dmso_a_209118 1213..1223

Diagnostic Potential of Serum Protein Pattern in Type 2 Diabetic Nephropathy

Plasma Targeted Metabolomics Analysis for Amino Acids and Acylcarnitines in Patients with Prediabetes, Type 2 Diabetes Mellitus, and Diabetic Vascular Complications

Proteomic analysis of diabetic retinopathy identifies potential plasma-protein biomarkers for diagnosis and prognosis

Identification of Immune Infiltration and the Potential Biomarkers in Diabetic Peripheral Neuropathy through Bioinformatics and Machine Learning Methods

Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study

Identification of a Non-Invasive Urinary Exosomal Biomarker for Diabetic Nephropathy Using Data-Independent Acquisition Proteomics

Serum and Urinary Metabolomic Analysis in Patients with Diabetic Nephropathy

Formate Might Be a Novel Potential Serum Metabolic Biomarker for Type 2 Diabetic Peripheral Neuropathy

Localized-statistical Quantification of Human Serum Proteome Associated with Type 2 Diabetes.

Lipidomics Reveals Serum Specific Lipid Alterations in Diabetic Nephropathy

Screening for Potential Serum-Based Proteomic Biomarkers for Human Type 2 Diabetes Mellitus Using Maldi-Tof Ms